Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
|Slideshows|March 15, 2019
Characteristics of Menopause: What Impact on Risk of CHD?
Author(s)Veronica Hackethal, MD
A new study found that age at menopause accounts for 10% of the link between menopause and coronary heart disease. Get more details in this quick slideshow.
Advertisement
Advertisement
Related to this article
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Advertisement
Advertisement
Trending on Patient Care Online
1
5 FDA Decisions for Primary Care to Know from September 2026
2
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
3
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
4
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
5